ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Ochre Bio has raised $30 million in series A funding to develop RNA therapies for chronic liver diseases. The UK start-up creates potential RNA therapies to reprogram the liver and tests them on discarded donor livers, which can be kept alive outside the body for multiple days. Ochre says it will use the funding to translate its research into drug candidates. It expects to move candidates to clinical development in 2024.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter